Zhejiang East Asia Pharmaceutical Co. Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents… Read more
Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) - Net Assets
Latest net assets as of September 2025: CN¥1.81 Billion CNY
Based on the latest financial reports, Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) has net assets worth CN¥1.81 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.39 Billion) and total liabilities (CN¥1.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.81 Billion |
| % of Total Assets | 53.54% |
| Annual Growth Rate | 20.34% |
| 5-Year Change | 8.39% |
| 10-Year Change | N/A |
| Growth Volatility | 33.87 |
Zhejiang East Asia Pharmaceutical Co. Ltd. - Net Assets Trend (2016–2024)
This chart illustrates how Zhejiang East Asia Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang East Asia Pharmaceutical Co. Ltd. (2016–2024)
The table below shows the annual net assets of Zhejiang East Asia Pharmaceutical Co. Ltd. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.87 Billion | -6.97% |
| 2023-12-31 | CN¥2.02 Billion | +9.54% |
| 2022-12-31 | CN¥1.84 Billion | +4.65% |
| 2021-12-31 | CN¥1.76 Billion | +1.65% |
| 2020-12-31 | CN¥1.73 Billion | +103.95% |
| 2019-12-31 | CN¥848.04 Million | +19.29% |
| 2018-12-31 | CN¥710.90 Million | +12.46% |
| 2017-12-31 | CN¥632.13 Million | +48.27% |
| 2016-12-31 | CN¥426.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang East Asia Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 337.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥506.05 Million | 27.00% |
| Common Stock | CN¥114.75 Million | 6.12% |
| Other Comprehensive Income | CN¥157.06 Million | 8.38% |
| Other Components | CN¥1.10 Billion | 58.51% |
| Total Equity | CN¥1.87 Billion | 100.00% |
Zhejiang East Asia Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Zhejiang East Asia Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LUBAWA SA
WAR:LBW
|
$166.08 Million |
|
Bajaj Hindusthan Sugar Limited
NSE:BAJAJHIND
|
$166.10 Million |
|
PT Map Aktif Adiperkasa Tbk
F:JN4
|
$166.16 Million |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
$166.20 Million |
|
Greaves Cotton Limited
NSE:GREAVESCOT
|
$166.06 Million |
|
Guangdong AVCiT Tech Hldg Co
SHE:001229
|
$166.00 Million |
|
Addcn Technology Co Ltd
TWO:5287
|
$165.95 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
$165.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang East Asia Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,015,273,151 to 1,874,615,395, a change of -140,657,756 (-7.0%).
- Net loss of 100,660,051 reduced equity.
- Dividend payments of 41,595,484 reduced retained earnings.
- Share repurchases of 25,001,291 reduced equity.
- Other comprehensive income increased equity by 157,055,158.
- Other factors decreased equity by 130,456,088.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-100.66 Million | -5.37% |
| Dividends Paid | CN¥41.60 Million | -2.22% |
| Share Repurchases | CN¥25.00 Million | -1.33% |
| Other Comprehensive Income | CN¥157.06 Million | +8.38% |
| Other Changes | CN¥-130.46 Million | -6.96% |
| Total Change | CN¥- | -6.98% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang East Asia Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.98x to 1.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥5.68 | CN¥22.60 | x |
| 2017-12-31 | CN¥8.05 | CN¥22.60 | x |
| 2018-12-31 | CN¥8.32 | CN¥22.60 | x |
| 2019-12-31 | CN¥7.47 | CN¥22.60 | x |
| 2020-12-31 | CN¥15.23 | CN¥22.60 | x |
| 2021-12-31 | CN¥15.48 | CN¥22.60 | x |
| 2022-12-31 | CN¥16.20 | CN¥22.60 | x |
| 2023-12-31 | CN¥16.12 | CN¥22.60 | x |
| 2024-12-31 | CN¥12.85 | CN¥22.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang East Asia Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.40%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.90x
- Recent ROE (-5.37%) is below the historical average (8.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 15.66% | 9.75% | 0.67x | 2.41x | CN¥24.11 Million |
| 2017 | 8.82% | 7.65% | 0.63x | 1.84x | CN¥-7.47 Million |
| 2018 | 15.38% | 12.76% | 0.78x | 1.54x | CN¥38.25 Million |
| 2019 | 19.85% | 17.04% | 0.89x | 1.30x | CN¥83.52 Million |
| 2020 | 6.62% | 12.98% | 0.42x | 1.20x | CN¥-58.47 Million |
| 2021 | 3.90% | 9.62% | 0.32x | 1.28x | CN¥-107.32 Million |
| 2022 | 5.68% | 8.85% | 0.48x | 1.34x | CN¥-79.55 Million |
| 2023 | 6.02% | 8.94% | 0.41x | 1.66x | CN¥-80.28 Million |
| 2024 | -5.37% | -8.40% | 0.34x | 1.90x | CN¥-288.12 Million |
Industry Comparison
This section compares Zhejiang East Asia Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang East Asia Pharmaceutical Co. Ltd. (605177) | CN¥1.81 Billion | 15.66% | 0.87x | $166.08 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |